// App-Quantinova.ai

NIMG-66 : AI-BASED PROGNOSTIC IMAGING BIOMARKERS FOR PRECISION NEUROONCOLOGY AND THE RESPOND CONSORTIUM

Researchers

Presenter

  • Christos Davatzikos

Principal Investigators

  • Anahita Fathi Kazerooni

  • Vishnu Bashyam

  • Spyridon Bakas

  • Rivka Colen

  • Abhishek Mahajan

  • Carmen Balaa

  • Jaume Capellades

  • Josep Puig

  • Rajan Jain

  • Andrew E Sloan

  • Daniel S Marcus

  • Yoon Seong Choi

  • Seung-Koo Lee

  • Jong Hee Chang

  • Laila M Poisson

  • Brent Griffith

  • Adam P Dicker

  • Adam E Flanders

  • Thomas C Booth

  • Saima Rathore

  • Hamed Akbari

  • Chiharu Sako

  • Michel Bilello

  • Gaurav Shukla

  • Steven Brem

  • Robert Lustig

  • Suyash Mohan

  • MacLean Nasrallah

  • Donald M ORourke

  • Stephen Bagley

  • Jill S Barnholtz-Sloan

Medical Centers

  • Case Western Reserve University and University Hospitals, Cleveland, OH

  • Tata Memorial Hospital, Mumbai, India

  • Catalan Institute of Oncology, Badalona, Spain

  • Hospital Del Mar, Barcelona, Spain

  • Hospital Universitario de Girona Dr Josep Trueta, Girona, Spain

  • University Hospitals Seidman Cancer Center,Case Comprehensive Cancer Center, Cleveland, OH

  • Washington University, St Louis, MO

  • Yonsei University College of Medicine, Singapore, Singapore

  • Yonsei University College of Medicine, Seoul, Korea

  • Yonsei University Health System, Seoul, Korea

  • Henry Ford Health System, Detroit, MI

  • Kings College London, London, United Kingdom

  • Case Western Reserve University, Cleveland, OH

Locations

  • United States

  • India

  • Spain

  • Singapore

  • Republic of South Korea

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • O-6-methylguanine DNA methyltransferase

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved